SCHEMBL659360

SCHEMBL659360

CCCCCCCCCOc1cc[c]cc1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR5A1 Q13285 1/20 0.60
LTA4H P09960 4/20 0.53
TP53 P04637 2/20 0.53
TSHR P16473 2/20 0.53
PLA2G4B P0C869 3/20 0.51
RARB P10826 3/20 0.49
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
RAB9A P51151 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PLA2G4A P47712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL338316 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL1609987 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL1611001 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL309133 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL987954 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL77477 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL9121701 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL263776 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL988767 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL1610778 1.00 NR5A1 (0.60) NR5A1LTA4HTP53TSHRPLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP claimed
EP-1454903-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP claimed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US claimed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US claimed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP claimed
EP-0267585-B1 FLUOROALKANE DERIVATIVE, ITS COMPOSITION AND LIQUID CRYSTAL DEVICE USING SAME CANON KABUSHIKI KAISHA (JP) 1993-09-15 EP claimed
US-4604471-A PLASTIC STABILIZERS BASF AKTIENGESELLSCHAFT (DE) 1986-08-05 US claimed
CN-111315828-B Composition, cured product, optical filter, and method for producing cured product 株式会社艾迪科 2023-09-29 CN disclosed
CN-112154167-B Composition, cured product, optical filter, and method for producing cured product 株式会社艾迪科 2023-08-22 CN disclosed
CN-110494501-B Phthalocyanine compound and use thereof 山本化成株式会社 2022-04-19 CN disclosed
WO-2022059590-A1 LIGHT- OR HEAT-RESPONSIVE CLEAVAGE MOLECULAR LAYER 国立研究開発法人産業技術総合研究所 2022-03-24 WO disclosed
CN-107151264-B Novel glycopeptide antibiotic derivative, pharmaceutical composition, preparation method and application thereof 浙江医药股份有限公司新昌制药厂 2021-11-23 CN disclosed
US-11015061-B2 Phthalocyanine-based compound and uses of same YAMAMOTO CHEMICALS, INC. (JP) 2021-05-25 US disclosed
US-4555355-A Composition for liquid crystal color display MITSUI TOATSU CHEMICALS, INC. (JP) 1985-11-26 US disclosed
EP-0143397-A2 Furan-3-hydroxamates and their use BASF Aktiengesellschaft (DE) 1985-06-05 EP disclosed
EP-0140133-A2 Liquid crystal phase-forming polymers BASF Aktiengesellschaft (DE) 1985-05-08 EP disclosed
EP-0060895-B1 COMPOSITION FOR LIQUID CRYSTAL COLOR DISPLAY MITSUI TOATSU CHEMICALS, Inc. (JP) 1985-05-02 EP disclosed
EP-0120463-A2 Anthraquinone dyes and liquid crystal compositions including the same HITACHI, LTD. (JP) 1984-10-03 EP disclosed
US-4459218-A Composition for liquid crystal color display MITSUI TOATSU CHEMICALS, INC. (JP) 1984-07-10 US disclosed
EP-0060895-A1 COMPOSITION FOR LIQUID CRYSTAL COLOR DISPLAY MITSUI TOATSU CHEMICALS, Inc. (JP) 1982-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 NR5A1 1667/4885LTA4H 2357/4885TP53 18/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 NR5A1 1667/4885LTA4H 2357/4885TP53 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.